Cargando…

Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study

Percutaneous microwave ablation therapy (PMCT) has been recommended for elderly hepatocellular carcinoma (HCC) patients who cannot tolerate surgery due to their age or presence of comorbidities. Few studies have investigated efficacy and treatment outcomes for PMCT treatment in these patients, espec...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xiaozhang, Ma, Sicong, Tang, Xiaoyin, Wang, Tao, Qi, Xingxing, Chi, Jiachang, Wang, Zhi, Cui, Dan, Zhang, Yuan, Li, Ping, Zhai, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393083/
https://www.ncbi.nlm.nih.gov/pubmed/30170369
http://dx.doi.org/10.1097/MD.0000000000011618
_version_ 1783398622049599488
author Shen, Xiaozhang
Ma, Sicong
Tang, Xiaoyin
Wang, Tao
Qi, Xingxing
Chi, Jiachang
Wang, Zhi
Cui, Dan
Zhang, Yuan
Li, Ping
Zhai, Bo
author_facet Shen, Xiaozhang
Ma, Sicong
Tang, Xiaoyin
Wang, Tao
Qi, Xingxing
Chi, Jiachang
Wang, Zhi
Cui, Dan
Zhang, Yuan
Li, Ping
Zhai, Bo
author_sort Shen, Xiaozhang
collection PubMed
description Percutaneous microwave ablation therapy (PMCT) has been recommended for elderly hepatocellular carcinoma (HCC) patients who cannot tolerate surgery due to their age or presence of comorbidities. Few studies have investigated efficacy and treatment outcomes for PMCT treatment in these patients, especially in China, where patients are more often diagnosed and treated early in life. This study evaluated the safety and efficacy of ultrasound-guided PMCT in treatment-naive elderly HCC patients, and analyzed risk factors associated with poor treatment outcomes. The 65 HCC patients in this retrospective study were divided into 2 groups: <65 years old or ≥65 years old. Patients received PMCT every month until tumor was unobservable and were then followed for 1 month after ablation. The primary clinical endpoint was the rate of complete tumor ablation, and secondary endpoints were progression-free survival and overall survival. Patients ≥65 years old had significantly poorer performance status than younger patients, but similar rates of complete ablation. Multiple tumors and hypertension were associated with a significantly higher risk of death, while higher postoperative alanine aminotransferase levels were associated with a significantly lower risk of death. Patients with tumor sizes >5 to ≤ 10 cm were at a significantly higher risk for disease progression than patients with tumor sizes >1 to ≤ 3 cm. Complete ablation significantly lowered the risk of disease progression. PMCT is safe and effective for patients ≥65 years of age, achieving total ablation in more than 90% of patients. Age and comorbidities did not affect clinical outcome.
format Online
Article
Text
id pubmed-6393083
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63930832019-03-15 Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study Shen, Xiaozhang Ma, Sicong Tang, Xiaoyin Wang, Tao Qi, Xingxing Chi, Jiachang Wang, Zhi Cui, Dan Zhang, Yuan Li, Ping Zhai, Bo Medicine (Baltimore) Research Article Percutaneous microwave ablation therapy (PMCT) has been recommended for elderly hepatocellular carcinoma (HCC) patients who cannot tolerate surgery due to their age or presence of comorbidities. Few studies have investigated efficacy and treatment outcomes for PMCT treatment in these patients, especially in China, where patients are more often diagnosed and treated early in life. This study evaluated the safety and efficacy of ultrasound-guided PMCT in treatment-naive elderly HCC patients, and analyzed risk factors associated with poor treatment outcomes. The 65 HCC patients in this retrospective study were divided into 2 groups: <65 years old or ≥65 years old. Patients received PMCT every month until tumor was unobservable and were then followed for 1 month after ablation. The primary clinical endpoint was the rate of complete tumor ablation, and secondary endpoints were progression-free survival and overall survival. Patients ≥65 years old had significantly poorer performance status than younger patients, but similar rates of complete ablation. Multiple tumors and hypertension were associated with a significantly higher risk of death, while higher postoperative alanine aminotransferase levels were associated with a significantly lower risk of death. Patients with tumor sizes >5 to ≤ 10 cm were at a significantly higher risk for disease progression than patients with tumor sizes >1 to ≤ 3 cm. Complete ablation significantly lowered the risk of disease progression. PMCT is safe and effective for patients ≥65 years of age, achieving total ablation in more than 90% of patients. Age and comorbidities did not affect clinical outcome. Wolters Kluwer Health 2018-08-21 /pmc/articles/PMC6393083/ /pubmed/30170369 http://dx.doi.org/10.1097/MD.0000000000011618 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Shen, Xiaozhang
Ma, Sicong
Tang, Xiaoyin
Wang, Tao
Qi, Xingxing
Chi, Jiachang
Wang, Zhi
Cui, Dan
Zhang, Yuan
Li, Ping
Zhai, Bo
Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study
title Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study
title_full Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study
title_fullStr Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study
title_full_unstemmed Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study
title_short Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study
title_sort clinical outcome in elderly chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (pmct): a strobe-compliant observational study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393083/
https://www.ncbi.nlm.nih.gov/pubmed/30170369
http://dx.doi.org/10.1097/MD.0000000000011618
work_keys_str_mv AT shenxiaozhang clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT masicong clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT tangxiaoyin clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT wangtao clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT qixingxing clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT chijiachang clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT wangzhi clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT cuidan clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT zhangyuan clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT liping clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy
AT zhaibo clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy